Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Tumor-Agnostic 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Cyclophosphamide 296Cytarabine 261fludarabine phosphate 218Rituximab 195fludarabine 182Methotrexate 152Whole-Body Irradiation 140Mycophenolic Acid 124Azacitidine 122Tacrolimus 116Busulfan 110Filgrastim 104Granulocyte Colony-Stimulating Factor 98Etoposide 91Peripheral Blood Stem Cell Transplantation 90Dexamethasone 89Vincristine 88Melphalan 80Cyclosporine 74Lenalidomide 73Daunorubicin 70Decitabine 69Clofarabine 69Antilymphocyte Serum 67Calcium Dobesilate 61venetoclax 60Doxorubicin 58Imatinib Mesylate 57Alemtuzumab 56ibrutinib 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × eryaspase × Other hematologic neoplasm × Clear all
NCT03267030 2024-03-15

Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase

Aarhus University Hospital

Phase 2 Completed
55 enrolled 9 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01810705 2022-02-21

ENFORCE

ERYtech Pharma

Phase 2 Completed
123 enrolled 8 charts
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡